SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a full-service Clinical Research Organization (CRO), announced today that it has completed the acquisition of Topstone Research, a Canadian-based specialty contract research organization (CRO) with Phase II-IV services and an unwavering commitment to quality and service flexibility.
The acquisition of Topstone enhances capabilities within Clinical Operations including project management, site feasibility, study-start-up, site management, clinical monitoring, pharmacovigilance, and medical monitoring to proactively address the increased demand from our customers for these services. Expanded capabilities include patient recruitment and retention, site engagement team, and medical safety and monitoring expertise to support investigators and sites with study conduct in an ethical, patient safety-focused approach.
“I am excited to combine two amazingly talented companies like Veristat and Topstone together,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “The acquisition is about more than just expanding and strengthening of our clinical operations and biometrics capabilities. The leadership, culture, and drive of our organizations pivot around providing impactful, quality solutions that bring new therapies to improve and enhance the lives of patients and their families. We will continue to pursue growth strategies to improve and expand our capabilities into new service offerings and geographies to pro-actively address the needs of our growing client base.”
The acquisition of Topstone harnesses complementary strengths, expertise, and scale to provide superior solutions and progressive approaches to mitigate risks and achieve meaningful outcomes for our customers. Our combined team of like-minded experts will continue to offer unique and flexible approaches to tackling the most complex clinical trial and regulatory submission challenges.
“I and the team at Topstone are thrilled to be part of Veristat,” stated Shaheen Limbada, CEO of Topstone, and now Executive Vice President of Clinical Operations at Veristat. “The acquisition by Veristat enhances our capabilities within clinical operations to proactively address the increased demand from our customers for these services. Our added people and service strengths will make us the “go-to” company for biopharmaceutical companies who need assistance in bringing new and novel therapies to patients worldwide.”
Over the coming months, Topstone will transition to the Veristat name and brand. The Veristat team now consists of nearly 300 experts, located in 6 offices providing highly strategic consulting and clinical operations and patient recruitment support to emerging, small and medium biopharmaceutical firms advancing their therapies through the clinical trial and regulatory submission process.
Veristat is a clinical research partner focused on supporting biopharmaceutical firms as they advance their therapies through the clinical development and regulatory submission process. Our work delivers meaningful clinical impact and our regulatory submission expertise is unrivaled in our industry. Veristat teams have worked on over 70 regulatory submission projects that have resulted in more than 40 submission approvals to date from various regulatory agencies around the world. Over the last 5 years alone, nearly 8% of new molecular entities (NMEs) approved by the FDA were supported by Veristat teams. Veristat aims is to propel even the most complex submissions to successful regulatory conclusions so that new therapies become available to improve and save lives. For more information, visit www.veristat.com.